These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21823168)

  • 21. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amantadine for weight gain associated with olanzapine treatment.
    Deberdt W; Winokur A; Cavazzoni PA; Trzaskoma QN; Carlson CD; Bymaster FP; Wiener K; Floris M; Breier A
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):13-21. PubMed ID: 15572269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.
    Lin Y; Peng Y; He S; Xu J; Shi Y; Su Y; Zhu C; Zhang X; Zhou R; Cui D
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):71-78. PubMed ID: 29410009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
    Melkersson K; Berinder K; Hulting AL
    Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of olanzapine on the PR and QT intervals in patients with schizophrenia.
    Suzuki Y; Ono S; Tsuneyama N; Sawamura K; Sugai T; Fukui N; Watanabe J; Someya T
    Schizophr Res; 2014 Jan; 152(1):313-4. PubMed ID: 24275577
    [No Abstract]   [Full Text] [Related]  

  • 27. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.
    Watanabe J; Suzuki Y; Fukui N; Ono S; Sugai T; Tsuneyama N; Someya T
    J Clin Psychopharmacol; 2012 Feb; 32(1):18-22. PubMed ID: 22198445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine.
    Lykouras L; Markianos M; Hatzimanolis J; Oulis P
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Apr; 25(3):507-18. PubMed ID: 11370994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating machine learning with electronic health record data to facilitate detection of prolactin level and pharmacovigilance signals in olanzapine-treated patients.
    Zhu X; Hu J; Xiao T; Huang S; Shang D; Wen Y
    Front Endocrinol (Lausanne); 2022; 13():1011492. PubMed ID: 36313772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
    Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
    Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia.
    Takeuchi H; Suzuki T; Remington G; Watanabe K; Mimura M; Uchida H
    J Clin Psychopharmacol; 2014 Aug; 34(4):517-20. PubMed ID: 24911439
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
    Shao P; Ou J; Wu R; Fang M; Chen H; Xu Y; Zhao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 38(4):365-9. PubMed ID: 23645236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in QT interval after switching to quetiapine in Japanese patients with schizophrenia.
    Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
    Hum Psychopharmacol; 2013 Jan; 28(1):94-6. PubMed ID: 23161621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
    Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
    Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
    J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
    Murashita M; Inoue T; Kusumi I; Nakagawa S; Itoh K; Tanaka T; Izumi T; Hosoda H; Kangawa K; Koyama T
    Psychiatry Clin Neurosci; 2007 Feb; 61(1):54-8. PubMed ID: 17239039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gender differences in prolactin elevation induced by olanzapine in Japanese drug-naïve schizophrenic patients.
    Sawamura K; Suzuki Y; Fukui N; Sugai T; Someya T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1511-4. PubMed ID: 16824658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.